Updated
Updated · CBS New York · Oct 24
Ryan Goepel Stays Cancer-Free for 2 Years After AML Trial Put 19 of 36 in Remission
Updated
Updated · CBS New York · Oct 24

Ryan Goepel Stays Cancer-Free for 2 Years After AML Trial Put 19 of 36 in Remission

1 articles · Updated · CBS New York · Oct 24

Summary

  • Two years after a near-fatal acute myeloid leukemia diagnosis, Florida father Ryan Goepel remains cancer-free following an adverse-risk AML clinical trial and a November 2024 bone marrow transplant.
  • Doctors steered him to the trial because standard chemotherapy was unlikely to control his genetically adverse-risk disease and could have killed him within weeks, according to his treating physician.
  • Just over two weeks after starting the regimen, Goepel entered remission; trial data later published in Haematologica showed 25 of 36 patients responded within 28 days and 19 reached complete remission.
  • The study also found patients spent less time in hospital, needed fewer transfusions and had fewer infections than with standard treatment, though experts said more research is still needed before changing long-standing AML care.

Insights

Could a drug combination meant for older patients become the new secret weapon against aggressive leukemia in younger adults?
Why might less intensive chemotherapy actually be more effective at curing high-risk leukemia than traditional aggressive treatments?
How can everyday knee pain suddenly reveal a deadly, fast-growing blood cancer hiding in your genetics?